Lupin Limited Manufacturing Facility Underwent U.S. FDA Inspection in New Jersey

Lupin Limited Manufacturing Facility Underwent U.S. FDA Inspection in New Jersey​

Lupin Limited confirmed that its manufacturing facility located in Somerset, New Jersey, U.S.A., recently underwent an inspection by the U.S. FDA. The inspection process took place from April 13, 2026, through April 17, 2026.

Upon conclusion of the review, the company received a Form-483 detailing three observations.

Lupin Limited stated that the company is committed to maintaining compliance with CGMP standards across all its facilities. The company plans to address the observations made during the inspection and will respond to the U.S. FDA within the stipulated timeframe.

LUPIN Stock Price Movement​

On Friday, Lupin Limited shares slipped by 0.19% to settle at ₹2326.1. The stock traded on heavy volume, with 999,957 shares exchanging hands during the session.

Source:​

Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.

The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.

Any views, opinions, or statements expressed, where applicable, are those of the respective analysts or experts and do not reflect the views of this website. The website has no association with such viewpoints and does not assume any responsibility for them.